# Reprogramming the immunosuppressive breast cancer microenvironment: integrating cellular, metabolic, and stromal targets for rational immunotherapy

**Authors:** Chang Ma, Hoon Koon Teoh, Yang Zhao, Yifan Wang, Jun Zhao, Yan Liu, Chen Zhao, Hooi Tin Ong

PMC · DOI: 10.3389/fimmu.2026.1760782 · Frontiers in Immunology · 2026-02-13

## TL;DR

This review explores how to change the immune environment in breast cancer to improve immunotherapy by targeting cells, metabolism, and tissue structure.

## Contribution

The paper introduces novel strategies like metabolic modulation and stromal reprogramming to enhance immunotherapy effectiveness.

## Key findings

- Immunosuppressive mechanisms in breast cancer TIME hinder treatment success.
- Combination therapies can convert 'cold' tumors into 'hot' immune-responsive ones.
- Spatial transcriptomics and liquid biopsy offer new ways to monitor and adapt immunotherapy.

## Abstract

Breast cancer, a highly heterogeneous malignancy and a leading cause of cancer-related mortality among women worldwide, is profoundly shaped in its initiation, progression, and therapeutic response by the tumor immune microenvironment (TIME). This review consolidates recent advances in deciphering the cellular, molecular, and metabolic complexity of breast cancer TIME and highlights mechanisms of immune suppression that impede durable treatment efficacy. We critically appraise current and emerging immunotherapeutic approaches, with a focus on strategies that aim to transform immunologically “cold” tumors into “hot,” immune-responsive phenotypes. Novel directions, including metabolic modulation, stromal reprogramming, and precision combination therapies, are discussed in the context of overcoming primary and acquired resistance. We highlight emerging biomarker strategies that integrate spatial transcriptomics to map immune exclusion zones, along with liquid biopsy monitoring of exosomal PD-L1 and circulating tumor DNA, to enable real-time adaptation of combination immunotherapy regimens.

## Linked entities

- **Proteins:** CD274 (CD274 molecule)
- **Diseases:** breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** CBLB (Cbl proto-oncogene B) [NCBI Gene 100621690], IFNG (interferon gamma) [NCBI Gene 396991], ADORA2A (adenosine A2a receptor) [NCBI Gene 135] {aka A2aR, ADORA2, RDC8}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, HLA-C (major histocompatibility complex, class I, C) [NCBI Gene 3107] {aka D6S204, HLA-JY3, HLAC, HLC-C, MHC, PSORS1}, NR4A1 (nuclear receptor subfamily 4 group A member 1) [NCBI Gene 3164] {aka GFRP1, HMR, N10, NAK-1, NGFIB, NP10}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, HAVCR2 (hepatitis A virus cellular receptor 2) [NCBI Gene 84868] {aka CD366, HAVcr-2, KIM-3, SPTCL, TIM3, TIMD-3}, MIR21 (microRNA mir-21) [NCBI Gene 100316568] {aka ssc-mir-21}, FGL1 (fibrinogen like 1) [NCBI Gene 100516651], CD163 (CD163 molecule) [NCBI Gene 9332] {aka M130, MM130, SCARI1}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}, IKZF2 [NCBI Gene 100510935], CCL8 (C-C motif chemokine ligand 8) [NCBI Gene 6355] {aka HC14, MCP-2, MCP2, SCYA10, SCYA8}, NT5E (5'-nucleotidase ecto) [NCBI Gene 4907] {aka CALJA, CD73, E5NT, NT, NT5, NTE}, TNFSF10 (TNF superfamily member 10) [NCBI Gene 8743] {aka APO2L, Apo-2L, CD253, TANCR, TL2, TNLG6A}, B3GAT1 (beta-1,3-glucuronyltransferase 1) [NCBI Gene 27087] {aka CD57, GLCATP, GLCUATP, HNK1, LEU7, NK-1}, FASLG (Fas ligand) [NCBI Gene 356] {aka ALPS1B, APT1LG1, APTL, CD178, CD95-L, CD95L}, SLA-DRB1 (MHC class II histocompatibility antigen SLA-DRB1) [NCBI Gene 100153386] {aka DRB1, LA-DRB-c, LA-DRB-d, SLA-DRB, SLADRB}, TCF7 (transcription factor 7) [NCBI Gene 6932] {aka TCF-1}, ENTPD1 (ectonucleoside triphosphate diphosphohydrolase 1) [NCBI Gene 953] {aka ATP-DPH, ATPDase, CD39, NTPDase-1, SPG64}, NCR1 (natural cytotoxicity triggering receptor 1) [NCBI Gene 9437] {aka CD335, LY94, NK-p46, NKP46}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, EGR3 (early growth response 3) [NCBI Gene 100516296], NFAT [NCBI Gene 396824], IL2RA (interleukin 2 receptor subunit alpha) [NCBI Gene 3559] {aka CD25, IDDM10, IL2R, IMD41, TCGFR, p55}, TEK (TEK receptor tyrosine kinase) [NCBI Gene 7010] {aka CD202B, GLC3E, TIE-2, TIE2, VMCM, VMCM1}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 100126861] {aka Akt, PKB}, TLR8 (toll like receptor 8) [NCBI Gene 397384] {aka TLR7}, IL33 (interleukin 33) [NCBI Gene 90865] {aka C9orf26, DVS27, IL1F11, NF-HEV, NFEHEV}, TOX (thymocyte selection associated high mobility group box) [NCBI Gene 100155888], CD226 (CD226 molecule) [NCBI Gene 10666] {aka DNAM-1, DNAM1, PTA1, TLiSA1}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, TRBV20OR9-2 (T cell receptor beta variable 20/OR9-2 (non-functional)) [NCBI Gene 6962] {aka CDR3, TCRBV20S2, TCRBV2O, TCRBV2S2O}, ACTA1 (actin alpha 1, skeletal muscle) [NCBI Gene 58] {aka ACTA, ASMA, CFTD, CFTD1, CFTDM, CMYO2A}, ANGPT2 (angiopoietin 2) [NCBI Gene 285] {aka AGPT2, ANG2, LMPHM10}, CTLA4 (cytotoxic T-lymphocyte associated protein 4) [NCBI Gene 397286], COL11A2 (collagen type XI alpha 2 chain) [NCBI Gene 1302] {aka DFNA13, DFNB53, FBCG2, HKE5, OSMEDA, OSMEDB}, FOXP3 (forkhead box P3) [NCBI Gene 50943] {aka AIID, DIETER, IPEX, JM2, PIDX, XPID}, EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) [NCBI Gene 2146] {aka ENX-1, ENX1, EZH2b, KMT6, KMT6A, WVS}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, ARG1 (arginase 1) [NCBI Gene 383], CXADRP1 (CXADR pseudogene 1) [NCBI Gene 653108] {aka CAR, CXADRP}, EDN1 (endothelin 1) [NCBI Gene 1906] {aka ARCND3, ET1, HDLCQ7, PPET1, QME}, IDO1 (indoleamine 2,3-dioxygenase 1) [NCBI Gene 3620] {aka IDO, IDO-1, INDO}, CBLB (Cbl proto-oncogene B) [NCBI Gene 868] {aka ADMIO3, Cbl-b, Nbla00127, RNF56}, ICAM1 (intercellular adhesion molecule 1) [NCBI Gene 3383] {aka BB2, CD54, P3.58}, JUN (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 396913] {aka C-JUN}, IL15 (interleukin 15) [NCBI Gene 3600] {aka IL-15}, DLL4 (delta like canonical Notch ligand 4) [NCBI Gene 54567] {aka AOS6, delta4, hdelta2}, TIGIT (T cell immunoreceptor with Ig and ITIM domains) [NCBI Gene 201633] {aka VSIG9, VSTM3, WUCAM}, VCAM1 (vascular cell adhesion molecule 1) [NCBI Gene 7412] {aka CD106, INCAM-100}, MRC1 (mannose receptor C-type 1) [NCBI Gene 4360] {aka CD206, CLEC13D, CLEC13DL, MMR, MRC1L1, bA541I19.1}, CD80 (CD80 molecule) [NCBI Gene 397161] {aka B7-1}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, CD28 [NCBI Gene 100738615], CD274 (CD274 molecule) [NCBI Gene 574058] {aka PDL1}, LAG3 (lymphocyte activating 3) [NCBI Gene 3902] {aka CD223}, TIGIT (T cell immunoreceptor with Ig and ITIM domains) [NCBI Gene 100624099]
- **Diseases:** malignancies (MESH:D009369), T cell dysfunction (MESH:C536780), inflammation (MESH:D007249), Hypoxia (MESH:D000860), TAM (MESH:D020914), hypoxic (MESH:D002534), obese (MESH:D009765), tumorigenesis (MESH:D063646), infection (MESH:D007239), T (MESH:D001260), cytotoxic (MESH:D064420), TDEs (MESH:C536408), MDSCs (OMIM:601308), tumorigenic (MESH:D002471), TAMs (MESH:D000072716), solid (MESH:D018250), TNBC (MESH:D064726), Breast cancer (MESH:D001943)
- **Chemicals:** lactate (MESH:D019344), Trastuzumab (MESH:D000068878), paraffin (MESH:D010232), adenosine (MESH:D000241), oxygen (MESH:D010100), kynurenine (MESH:D007737), bevacizumab (MESH:D000068258), lactyl-CoA (MESH:C047009), abemaciclib (MESH:C000590451), pembrolizumab (MESH:C582435), fatty acid (MESH:D005227), L-arginine (MESH:D001120), AZD4635 (-), H&amp;E (MESH:D006371), hematoxylin (MESH:D006416), eosin (MESH:D004801), tryptophan (MESH:D014364), formalin (MESH:D005557), glucose (MESH:D005947), ATP (MESH:D000255), glutamine (MESH:D005973), lipid (MESH:D008055)
- **Species:** Mycoplasma (genus) [taxon 2093], Fusobacterium (genus) [taxon 848], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** A2A

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12946151/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12946151/full.md

## References

170 references — full list in the complete paper: https://tomesphere.com/paper/PMC12946151/full.md

---
Source: https://tomesphere.com/paper/PMC12946151